Quo Vadis Continuous?

GEA Presents the Status Quo

Taking place in Ghent, Belgium, on 11–13 October, GEA experts will discuss the current status of continuous pharmaceutical manufacturing during 3-day a training course.

Perfectly timed to reflect the US FDA’s recent guidance on emerging manufacturing technologies, GEA’s Joel Aerts and Jake Deighton will share the podium on day one with Prof. Thomas De Beer to discuss the “status quo of continuous manufacturing (CM)” and present a case study on “Design space determination of a continuous tablet manufacturing process via wet granulation through empirical process models.”

GEA has spearheaded the development of state-of-the-art CM technologies and solutions to produce pharmaceutical oral solid dosage forms for the last decade. The company’s highly versatile patented ConsiGma? manufacturing platforms combine multiple functionalities into one single, closed unit that convert powdered raw materials into finished drug product.

And, in an ongoing effort to help pharmaceutical companies better negotiate the regulatory submission process, shorten timelines, reduce risk and expedite drug development from R&D through tech transfer to commercial production, GEA is now working with the Research Center for Pharmaceutical Engineering GmbH (RCPE) in Austria to facilitate the industrial implementation of CM technologies.

To learn more about the event and for further information about GEA’s processes, products and solutions, contact our experts at gea.com/contact or via “The next generation pharma skills you will need in view of continuous manufacturing” website.